Glycoprotein IIb/IIIa inhibitors for heart attack and unstable angina
Examples
| abciximab |
ReoPro |
| eptifibatide |
Integrilin |
| tirofiban |
Aggrastat |
How It Works
These medicines prevent the formation of
blood clots.
Why It Is Used
Glycoprotein IIb/IIIa inhibitors are
typically used along with angioplasty, stenting, or atherectomy procedures.
Glycoprotein IIb/IIIa inhibitors help prevent reclosure of the blood vessel
(restenosis) after these procedures. These medicines are often used along with
aspirin and heparin.
How Well It Works
Glycoprotein IIb/IIIa inhibitors may
reduce the chance of a heart attack when used after angioplasty with stenting
and in people who have unstable angina. Although these medicines appear to be
useful when given immediately after angioplasty and stenting, long-term use has
not proved beneficial.
Glycoprotein IIb/IIIa inhibitors may lower
the risk of death in people who have angioplasty after a heart attack.1
Side Effects
Some side effects of these medicines may
include:
- Increased bleeding (hemorrhage) in the brain,
stomach, intestines, or other internal organs.
- Increased
bruising.
- Stomach irritation.
- Allergic reaction.
See Drug Reference for a full list of side effects. (Drug
Reference is not available in all systems.)
What To Think About
Glycoprotein IIb/IIIa inhibitors
are only used in the hospital, such as before or after an angioplasty.
Complete the new medication information form (PDF)(What is a PDF document?)
to help you understand this medication.
References
Citations
-
De Luca G, et al. (2005). Abciximab as adjunctive
therapy to reperfusion in acute ST-segment elevation myocardial infarction: A
meta-analysis of randomized trials. JAMA, 293(14):
1759–1765.
Last Updated:
May 5, 2009
De Luca G, et al. (2005). Abciximab as adjunctive
therapy to reperfusion in acute ST-segment elevation myocardial infarction: A
meta-analysis of randomized trials. JAMA, 293(14):
1759–1765.